Proietto J, Alford F P, Dudley F J
J Clin Endocrinol Metab. 1980 Nov;51(5):1030-6. doi: 10.1210/jcem-51-5-1030.
Cirrhosis of the liver is frequently associated with carbohydrate intolerance but it is unknown whether this intolerance is due to increased hepatic glucose production (HGP), decreased glucose utilization, or both. HGP and the MCR of glucose [(MCR)G] were measured at steady state, basally and during an infusion of insulin (25 mU/kg x h) and glucose (11 mumol/kg x min), in 11 cirrhotics and 8 controls using the technique of a primed constant infusion of [3H]3-glucose. HGP was also estimated at nonsteady state during an infusion of glucagon (8 ng/kg x min). Basal HGP was significantly lower in cirrhotics compared to controls (10.2 +/- 0.6 vs. 13.2 +/- 0.6 mumol/kg x min; P < 0.0025). During the insulin/glucose infusion, HGP was suppressed to the same degree in both groups [in controls by 83% (13.2 +/- 0.6 to 2.2 +/- 0.8 mumol/kg x min) and in cirrhotics by 87% (10.2 +/- 0.6 to 1.3 +/- 0.4 mumol/kg x min)]. After the glucagon infusion, HGP rose by a similar degree in cirrhotics and controls. In contrast, basal (MCR)G was significantly lower in the nondiabetic cirrhotics (2.1 +/- .02 ml/kg x min; P < 0.005) and diabetic cirrhotics (1.2 +/- 0.2 ml/kg x min; P < 0.0005) compared to that in the control subjects (2.8 +/- 0.2 ml/kg x min). Moreover, there was a highly significant (P < 0.001) negative correlation between basal (MCR)G and the fasting glucose level (r = 0.82), and the degree of glucose intolerance as expressed by the 2-h glucose level determined by the oral glucose tolerance test (r = 0.87). It is concluded that the glucose intolerance of cirrhosis is due to a defect in peripheral glucose utilization.
肝硬化常伴有碳水化合物不耐受,但尚不清楚这种不耐受是由于肝脏葡萄糖生成增加(HGP)、葡萄糖利用减少,还是两者兼而有之。采用[3H]3-葡萄糖的单次恒速输注技术,在11例肝硬化患者和8例对照者中,于基础状态以及在输注胰岛素(25 mU/kg·h)和葡萄糖(11 μmol/kg·min)期间,测量了稳态下的HGP和葡萄糖代谢清除率(MCR)G。在输注胰高血糖素(8 ng/kg·min)期间,还在非稳态下估计了HGP。与对照组相比,肝硬化患者的基础HGP显著降低(10.2±0.6 vs. 13.2±0.6 μmol/kg·min;P<0.0025)。在胰岛素/葡萄糖输注期间,两组的HGP均被抑制到相同程度[对照组降低83%(13.2±0.6至2.2±0.8 μmol/kg·min),肝硬化患者降低87%(10.2±0.6至1.3±0.4 μmol/kg·min)]。胰高血糖素输注后,肝硬化患者和对照者的HGP升高程度相似。相比之下,与对照受试者(2.8±0.2 ml/kg·min)相比,非糖尿病肝硬化患者(2.1±0.02 ml/kg·min;P<0.005)和糖尿病肝硬化患者(1.2±0.2 ml/kg·min;P<0.00